Skip to main content
. 2018 Aug 16;25(3):314–322. doi: 10.1111/cns.13040

Figure 4.

Figure 4

Comparison of the therapeutic prognostic value of different CpG combinations for glioblastoma patient survival. A‐C, Therapeutic prognostic effects of the MGMT methylation statuses determined by CpGs 75‐82 (A), CpGs 76‐79 (B), and CpGs 75‐78(C) for glioblastoma patient OS were evaluated by ROC in the eight‐site cohort. D‐F,Therapeutic prognostic effects of the MGMT methylation statuses determined by CpGs 72‐78 (D), CpGs 74‐79 (E), and CpGs 75‐78(F) for glioblastoma patient OS were evaluated by ROC in the seven‐site cohort